Diagnostic accuracy of 14‐3‐3 η protein in rheumatoid arthritis: A meta‐analysis

Wang, Decai; Cui, Yalan; Lei, Huiren; Cao, Ding; Tang, Guoting; Huang, Haiming; Yuan, Ting; Rao, Lizong; Mo, Biwen

doi:10.1111/1756-185x.13921

Cited by 10 publications

(9 citation statements)

References 37 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As can be seen from the table, the sensitivity and specificity vary widely but are consistently good with a meta-analysis of all studies estimating that a pooled sensitivity was 73% (95% CI: 71, 75) and the pooled specificity was 88% (95% CI: 87, 90). [ 21 ] This provides evidence that it could be a very useful bio-marker for diagnosis. Another pooled meta-analysis [ 22 ] showed that a pooled sensitivity of 14-3-3 η as 0.63 (95% CI: 0.60–0.66) and the pooled specificity as 0.90 (95% CI: 0.88–0.91).…”

Section: Resultsmentioning

confidence: 99%

The role of 14-3-3 η as a biomarker in rheumatoid arthritis

Abdelhafiz

Kilborn

Bukhari

2021

Rheumatology and Immunology Research

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic multisystem inflammatory disorder with significant morbidity and mortality. Making an early diagnosis and providing appropriate treatment decisions based on clinical and other parameter results in good disease control. Biomarkers, such as C reactive protein (CRP), anti-cyclic citrullinated peptides (anti-CCP), and erythrocyte sedimentation rate (ESR), have been traditionally used. Recently novel biomarkers are described. This article reviews the evidence behind a novel biomarker 14-3-3 η that has been found to provide additional diagnostic and prognostic information as well as predicting response to treatment. A systematic literature review is presented showing the evidence behind this molecule.

show abstract

Section: Resultsmentioning

confidence: 99%

The role of 14-3-3 η as a biomarker in rheumatoid arthritis

Abdelhafiz

Kilborn

Bukhari

2021

Rheumatology and Immunology Research

View full text Add to dashboard Cite

show abstract

“…In a recent study, a panel of 4 biomarkers distinguished established RA patients from healthy controls with an AUC of >0.97 (32). Another study showed the ability of the RA‐associated 14‐3‐3 η protein (33) to distinguish RA from healthy controls with an ROC AUC of >0.92 for RA according to the ACR 1987 classification criteria (34). However, when combined with anti‐CCP and RF, the 30% false‐positive rate (34) may limit the clinical utility.…”

Section: Discussionmentioning

confidence: 99%

Autoantibodies to Disease‐Related Proteins in Joints as Novel Biomarkers for the Diagnosis of Rheumatoid Arthritis

Lönnblom

Agelii

Sareila

et al. 2023

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective. This study was undertaken to develop and characterize a multiplex immunoassay for detection of autoantibodies against peptides derived from proteins known to play a role in development of arthritis and that are also expressed in joints.Methods. We selected peptides from the human counterpart of proteins expressed in the joints, based on mouse models that showed these to be targeted by pathogenic or regulatory antibodies in vivo. Using bead-based flow immunoassays measuring IgG antibodies, we selected triple helical or cyclic peptides, containing the epitopes, to avoid collinear reactivity. We characterized the analytical performance of the immunoassay and then validated it in 3 independent rheumatoid arthritis (RA) cohorts (n = 2,110), Swedish age-and sex-matched healthy controls, and patients with osteoarthritis (OA), patients with psoriatic arthritis (PsA), and patients with systemic lupus erythematosus (SLE).Results. Screening assays showed 5 peptide antigens that discriminated RA patients from healthy controls with 99% specificity (95% confidence interval [CI] 98-100%). In our validation studies, we reproduced the discriminatory capacity of the autoantibodies in 2 other RA cohorts, showing that the autoantibodies had high discriminatory capacity for RA versus OA, PsA, and SLE. The novel biomarkers identified 22.5% (95% CI 19-26%) of early RA patients seronegative for anti-cyclic citrullinated peptide and rheumatoid factor. The usefulness of the biomarkers in identifying seronegative RA patients was confirmed in validation studies using 2 independent cohorts of RA patients and cohorts of patients with OA, PsA, and SLE.Conclusion. A multiplex immunoassay with peptides from disease-related proteins in joints was found to be useful for detection of specific autoantibodies in RA serum. Of note, this immunoassay had high discriminatory capacity for early seronegative RA.

show abstract

“…But when we compared the expression of the LRFN4 in PCa samples with different TNM staging, we noticed that the LRFN4 was upregulated in the patients with more advanced staging. The YWHA family proteins have been discovered to bind to various proteins such as transmembrane receptors and transcription factors, participating in intracellular protein transport, cell proliferation, apoptosis and signal transduction, etc (Wang et al 2020). It has been reported that the YWHAZ protein can enhance androgen receptor transcriptional activity in PCa and promote the adhesion and migration of various extracellular matrix proteins (Goc et al 2012;Murata et al 2012).…”

Section: Lrfn Protein Interaction Network Constructionmentioning

confidence: 99%

Expression and prognostic value of LRFN family genes in prostate cancer by integrated bioinformatics analysis

Pan

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

To analysis the expression of Leucine‑rich repeat fibronectin type 3 domain containing family genes(LRFNs) in prostate cancer (PCa) and its relationship with clinical features and prognosis. The PCa gene expression profiles were collected from UCSC Xena, and corresponding clinical information was extracted from the cBioPortal website. R and Cytoscape software and online tools such as HPA, cBioPortal, LinkedOmics, String, Metascape, and TIMER2 were used for bioinformatics analysis. LRFN1/2 were upregulated in various tumor tissues, including PCa, while the expression of LRFN3/4/5 were downregulated. LRFN1/2/4 were associated with disease-free survival (DFS) in PCa. LRFN4 was also associated with Gleason score and TNM staging. The protein-protein interaction (PPI) network analysis indicates that the LRFN protein family binds to the Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation protein or 14-3-3 protein(YWHA). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that the LRFNs and its 250 co-expressed genes are involved in protein binding and transmembrane transport, cell cycle regulation, and the PI3K-Akt pathway, etc. Besides, upregulation of the LRFN5 was correlated with the increased infiltration of immune cells such as B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils, dendritic cells, and the increased expression levels of various immune molecules. LRFNs have an essential role in the development and progression of PCa. LRFN1/2 expression is upregulated in PCa and LRFN3/4/5 expression is downregulated; LRFN1/2/4 may serve as potential prognostic biomarkers in PCa. LRFN3 and LRFN5 may be involved in regulating alterations of the immune microenvironment in PCa tumors.

show abstract

Diagnostic accuracy of 14‐3‐3 η protein in rheumatoid arthritis: A meta‐analysis

Cited by 10 publications

References 37 publications

The role of 14-3-3 η as a biomarker in rheumatoid arthritis

The role of 14-3-3 η as a biomarker in rheumatoid arthritis

Autoantibodies to Disease‐Related Proteins in Joints as Novel Biomarkers for the Diagnosis of Rheumatoid Arthritis

Expression and prognostic value of LRFN family genes in prostate cancer by integrated bioinformatics analysis

Contact Info

Product

Resources

About